MDI
0.035
75%
M2R
0.002
-33.3%
FBM
0.037
54.2%
PRX
0.002
-33.3%
COD
0.16
45.5%
DY6
0.22
-26.7%
TEM
0.007
40%
BKT
0.021
-22.2%
MEM
0.004
33.3%
1CG
0.01
-16.7%
EV1
0.015
25%
MGU
0.01
-16.7%
FRX
0.01
25%
RWL
0.15
-16.7%
HMX
0.032
23.1%
IFG
0.026
-16.1%
NIM
0.08
23.1%
ITM
0.054
-15.6%
HMG
0.089
21.9%
BNL
0.006
-14.3%
VRX
0.14
21.7%
OIL
0.09
-14.3%
GMN
0.08
21.2%
ECS
0.007
-12.5%
DUG
1.91
20.9%
WWG
0.14
-12.5%
AIS
0.265
20.5%
S2R
0.115
-11.5%
T92
0.065
20.4%
ANR
0.008
-11.1%
ALM
0.006
20%
APC
0.008
-11.1%
OSX
0.012
20%
GML
0.048
-11.1%
GSM
0.013
18.2%
M3M
0.032
-11.1%
ZEU
0.02
17.6%
OVT
0.008
-11.1%
GL1
0.275
17%
ATG
0.29
-10.8%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NTI Completed patient recruitment for its clinical trial for children with Autism

Neurotech International (ASX:NTI) completed patient recruitment for its Phase II/III NTIASD2 clinical trial for children with Autism. Patients recruited require substantial support and very substantial support autism | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231219/pdf/05yq6fqpsynsvp.pdf #Autism #shorts